This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Europe's premier partnering event
November 4–6, 2024 | Stockholm, SwedenNovember 12–13, 2024 | Digital Partnering

SiSaf Ltd


SiSaf is an RNA delivery and therapeutics company. Our proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon. SiSaf’s Bio-Courier technology combines a proprietary bioabsorbable silicon matrix with surface lipids and amino acids, a structure that addresses several of the major limitations and concerns associated with lipid nanoparticles to deliver RNA therapeutics. Silicon’s durable electrostatic potential helps bind and stabilise RNA reducing the need for potentially toxic cationic lipids and averting the risk of premature detachment of RNA. The high structural integrity of the silicon metalloid matrix prevents collapse on freeze drying and reduces the need for PEGylation, a key step to avoid the need for ultra-cold supply chain storage. SiSaf is developing a growing pipeline of RNA therapeutics for rare diseases. These therapeutics utilize the fundamental features of the company’s proprietary Bio-Courier delivery platform: durable RNA stabilization, non-immunogenic, efficient transfection, and no accumulation.